1. First Clinical Results of the Merit WRAPSODY™ Cell-Impermeable Endoprosthesis for Treatment of Access Circuit Stenosis in Haemodialysis Patients
- Author
-
Jason Rai, James A. Gilbert, John L. Skousen, David B. Kingsmore, and Nikolaos Ptohis
- Subjects
Target lesion ,medicine.medical_specialty ,Basilic Vein ,Fistula ,Arteriovenous fistula ,Constriction, Pathologic ,Anastomosis ,Covered stent ,End stage renal disease ,Cohort Studies ,End-stage renal disease ,Blood Vessel Prosthesis Implantation ,Spinal Stenosis ,Arteriovenous Shunt, Surgical ,Renal Dialysis ,Stent graft ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Clinical Investigation ,Letter to the Editor ,Vascular Patency ,Stenosis ,Occlusion ,business.industry ,Graft Occlusion, Vascular ,Prostheses and Implants ,medicine.disease ,Arteriovenous access ,Blood Vessel Prosthesis ,Surgery ,Haemodialysis ,Treatment Outcome ,Endoprosthesis ,Arteriovenous graft ,Cardiology and Cardiovascular Medicine ,business ,Cohort study - Abstract
Purpose This prospective, observational first in human study evaluated the safety and effectiveness of WRAPSODYTM Cell-impermeable Endoprosthesis (Merit Medical Systems, Inc.) in the treatment of arteriovenous fistula and arteriovenous graft access circuit stenosis. Materials and Methods Investigators conducted a prospective analysis of 46 patients with access circuit stenosis from three centres. Treatment sites included the peripheral outflow veins (e.g. cephalic arch, basilic vein swing point; 16 fistula and 10 graft patients); the graft-vein anastomosis (9 patients); and the central veins (up to, but not including the SVC; 11 patients). Primary outcome measures included 30-day freedom from access circuit-related safety events and 30-day target lesion primary patency. Secondary outcome measures included procedural success; device- and procedure-related adverse events; target lesion primary patency; access circuit primary patency; and secondary patency. In-person follow-up was scheduled at 1, 3, 6, and 12 months. An independent data monitoring/clinical event committee adjudicated all reinterventions and device/procedure-relatedness for adverse events. Results All initial procedures were successful. All but one patient was free from safety events through the first 30 days (97.8% (45/46)). This event was not device-related. Over the remainder of the study, one adverse event was adjudicated as possibly device-related. Six- and 12-month target lesion primary patency rates were 97.7% (42/43) and 84.6.% (33/39), respectively. Six- and 12-month access circuit primary patency rates were 84.4% (38/45) and 65.9% (29/44), respectively. Conclusion Results suggest that the study device is safe and effective for treatment of stenoses in the peripheral and central veins of arteriovenous access circuits. Level of Evidence Level 2b, cohort study.
- Published
- 2021
- Full Text
- View/download PDF